Design Therapeutics Shares Outstanding History (DSGN)
Design Therapeutics reported 60.4M shares outstanding at the end of fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 60.4M | 3.6M | +6.42% |
| 2024 | 2024-12-31 | 56.8M | 280,743 | +0.50% |
| 2023 | 2023-12-31 | 56.5M | 578,002 | +1.03% |
| 2022 | 2022-12-31 | 55.9M | 453,670 | +0.82% |
| 2021 | 2021-12-31 | 55.4M | 39.5M | +247.43% |
| 2020 | 2020-12-31 | 16.0M | — | — |
Design Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 62.6M | 5.6M | +9.89% |
| Q1 2026 | 2026-03-31 | 62.4M | 5.7M | +9.99% |
| Q4 2025 | 2025-12-31 | 60.4M | 3.6M | +6.42% |
| Q3 2025 | 2025-09-30 | 57.0M | 342,720 | +0.61% |
| Q2 2025 | 2025-06-30 | 56.9M | 328,112 | +0.58% |
| Q1 2025 | 2025-03-31 | 56.8M | 274,407 | +0.49% |
| Q4 2024 | 2024-12-31 | 56.8M | 280,743 | +0.50% |
| Q3 2024 | 2024-09-30 | 56.6M | 623,050 | +1.11% |
| Q2 2024 | 2024-06-30 | 56.6M | 640,815 | +1.14% |
| Q1 2024 | 2024-03-31 | 56.5M | 574,710 | +1.03% |
| Q4 2023 | 2023-12-31 | 56.5M | 578,002 | +1.03% |
| Q3 2023 | 2023-09-30 | 56.0M | 157,362 | +0.28% |
| Q2 2023 | 2023-06-30 | 56.0M | 262,438 | +0.47% |
| Q1 2023 | 2023-03-31 | 55.9M | 301,235 | +0.54% |
| Q4 2022 | 2022-12-31 | 55.9M | 453,670 | +0.82% |
| Q3 2022 | 2022-09-30 | 55.8M | 616,205 | +1.12% |
| Q2 2022 | 2022-06-30 | 55.7M | 602,032 | +1.09% |
| Q1 2022 | 2022-03-31 | 55.6M | 575,776 | +1.05% |
| Q4 2021 | 2021-12-31 | 55.4M | 45.7M | +466.31% |
| Q3 2021 | 2021-09-30 | 55.2M | — | — |
| Q2 2021 | 2021-06-30 | 55.1M | — | — |
| Q1 2021 | 2021-03-31 | 55.0M | — | — |
| Q4 2020 | 2020-12-31 | 9.8M | — | — |
Design Therapeutics shares outstanding trends
Over the last five reported fiscal years, Design Therapeutics's shares outstanding moved from 16.0M to 60.4M, a change of 44.4M. The latest reported quarter, Q2 2026, shows 62.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics filings at SEC.gov ↗